Lymph node surgery for melanoma with immunotherapy
Part of Cancer, Skin clinical trials.
This trial tests if a specific type of lymph node surgery, combined with a short course of immunotherapy (medicines that help your immune system fight cancer), works better for melanoma that has spread to nearby lymph nodes. It's for people whose melanoma can be removed and who are healthy enough for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma that has spread to one or more lymph nodes in your groin, armpit, or neck (and possibly nearby skin or tissue), and it can be removed by surgery.
- You haven't had more than a sentinel lymph node biopsy (a limited check) in the same area before.
- You haven't had radiation to the same area, and you haven't had certain other cancer treatments before.
- You are generally healthy (able to do daily activities without help) and expected to live at least 5 more years.
- You are willing to receive immunotherapy (like nivolumab, pembrolizumab, or similar) for up to 6 weeks before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery helps treat melanoma that has spread to nearby lymph nodes or a small number of other sites. The goal is to shrink tumors and improve surgical outcomes.
This trial tests whether removing a clinically involved lymph node basin (via a specific lymph node excision surgery) after certain melanoma findings is helpful. It mainly aims to see effects on outcomes and on arm/leg swelling (lymphedema) after surgery.
This trial tests whether patients with stage 3 melanoma that shrinks significantly after initial immunotherapy can safely avoid having all their lymph nodes surgically removed. Instead, only the main affected node is removed for testing.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
Hear when a new Cutaneous Melanoma, Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.